[go: up one dir, main page]

HUE066003T2 - Szisztémás, allogén eredetû õssejtterápiák kutyákban és macskákban betegségek kezelésére - Google Patents

Szisztémás, allogén eredetû õssejtterápiák kutyákban és macskákban betegségek kezelésére

Info

Publication number
HUE066003T2
HUE066003T2 HUE11822565A HUE11822565A HUE066003T2 HU E066003 T2 HUE066003 T2 HU E066003T2 HU E11822565 A HUE11822565 A HU E11822565A HU E11822565 A HUE11822565 A HU E11822565A HU E066003 T2 HUE066003 T2 HU E066003T2
Authority
HU
Hungary
Prior art keywords
cats
dogs
systemic
diseases
treatment
Prior art date
Application number
HUE11822565A
Other languages
English (en)
Hungarian (hu)
Inventor
Erik Woods
Sreedhar Thirumala
Shelly Zacharias
Original Assignee
Gallant Pet Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gallant Pet Inc filed Critical Gallant Pet Inc
Publication of HUE066003T2 publication Critical patent/HUE066003T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
HUE11822565A 2010-08-31 2011-08-31 Szisztémás, allogén eredetû õssejtterápiák kutyákban és macskákban betegségek kezelésére HUE066003T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37845710P 2010-08-31 2010-08-31

Publications (1)

Publication Number Publication Date
HUE066003T2 true HUE066003T2 (hu) 2024-06-28

Family

ID=45697573

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11822565A HUE066003T2 (hu) 2010-08-31 2011-08-31 Szisztémás, allogén eredetû õssejtterápiák kutyákban és macskákban betegségek kezelésére

Country Status (13)

Country Link
US (6) US20120052049A1 (fr)
EP (1) EP2611906B1 (fr)
JP (2) JP2013536860A (fr)
CN (1) CN103180435A (fr)
AU (1) AU2011295954B2 (fr)
BR (1) BR112013004917A2 (fr)
CA (1) CA2809272A1 (fr)
DK (1) DK2611906T3 (fr)
ES (1) ES2974955T3 (fr)
HU (1) HUE066003T2 (fr)
PL (1) PL2611906T3 (fr)
PT (1) PT2611906T (fr)
WO (1) WO2012030968A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542120C (fr) 2003-10-08 2018-07-10 Vet-Stem Inc. Procedes de preparation et d'utilisation de nouvelles compositions de cellules souches, et kits contenant ces dernieres
WO2012048099A2 (fr) * 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Cellules chargées de nanoparticules
EP2961329B1 (fr) 2013-02-27 2018-02-21 Med Invent Devices Private Limited Dispositif permettant le grossissement et prévenant la constriction de la pupille de l'oeil
US20140314872A1 (en) * 2013-04-22 2014-10-23 Hans Klingemann Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction
US10058572B2 (en) 2013-08-15 2018-08-28 The Regents Of The University Of California Placenta-derived multipotent stem cells
AU2014312421A1 (en) 2013-08-27 2016-04-14 Cook General Biotechnology Llc Bioactive compositions derivable from platelet concentrates, and methods for preparing and using same
EA024138B1 (ru) * 2013-10-17 2016-08-31 Акционерное Общество "Научный Центр Урологии Имени Академика Б.У. Джарбусынова" Способ проведения клеточной терапии для лечения экспериментального хронического орхоэпидидимита
EA025096B1 (ru) * 2013-10-17 2016-11-30 Акционерное Общество "Научный Центр Урологии Имени Академика Б.У. Джарбусынова" Способ проведения клеточной терапии для лечения экспериментального хронического орхоэпидидимита
CA2928122C (fr) * 2013-12-06 2023-12-12 Global Stem Cell Technology Procede et composition d'induction de chondrogenese ou de tenogenese dans des cellules souches mesenchymateuses
MX2016007926A (es) * 2013-12-19 2016-12-15 Université de Liège Celulas madre derivadas de musculo de mamifero.
WO2015120268A1 (fr) 2014-02-06 2015-08-13 Stryker European Holdings I, Llc Prélèvement et stockage de moelle osseuse
WO2016015007A1 (fr) 2014-07-25 2016-01-28 Recellerate, Inc. Méthodes de traitement d'une hémorragie pulmonaire induite par l'exercice physique
JP2017531446A (ja) * 2014-09-29 2017-10-26 クック・ジェネラル・バイオテクノロジー・エルエルシー 細胞懸濁液中のトレハロースの使用
MA40996A (fr) * 2014-11-17 2017-09-26 Univ Miami Matériaux et procédés de traitement d'un dysfonctionnement endothélial et procédés de surveillance de l'efficacité du traitement chez un patient
CN107257687B (zh) * 2014-12-23 2021-12-03 迈索布拉斯特国际有限公司 用于治疗心力衰竭的方法
WO2016111899A1 (fr) * 2015-01-05 2016-07-14 Petrucci Gary M Procédés et matériels pour le traitement de troubles pulmonaires
US10231743B2 (en) 2015-03-24 2019-03-19 Stryker European Holdings I, Llc Bone marrow harvesting device and storage methods
WO2017022628A1 (fr) * 2015-07-31 2017-02-09 国立大学法人大阪大学 Procédé d'évaluation d'efficacité de traitement et/ou de prévention de maladie épithéliale, procédé de sélection pour agent de traitement de maladie épithéliale, et agent de traitement de maladie épithéliale
AU2016321448B2 (en) * 2015-09-08 2023-02-02 Cell Ideas Pty Ltd Cell expansion methods and therapeutic compositions
JP6739758B2 (ja) * 2015-09-25 2020-08-12 三菱瓦斯化学株式会社 細胞培養用基材およびそれを用いた細胞培養方法、細胞培養器、並びに基材としての使用
CN106085954A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 一种大量人外周血pbmc快速分离方法
CN106265744A (zh) * 2016-09-29 2017-01-04 广州赛莱拉干细胞科技股份有限公司 脐带间充质干细胞在制备治疗角膜损伤的干细胞制剂中的应用
IL266561B2 (en) * 2016-11-11 2024-06-01 Longeveron Inc Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
US10478531B2 (en) 2017-06-22 2019-11-19 Gary M. Petrucci Methods and materials for treating blood vessels
US10251917B1 (en) 2017-09-19 2019-04-09 Gary M. Petrucci Methods and materials for treating tumors
CN119033819A (zh) 2017-11-22 2024-11-29 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
EP4130252A1 (fr) * 2018-02-16 2023-02-08 NextCell Pharma AB Composition allogénique de cellules souches mésenchymales
US11413314B2 (en) * 2018-06-15 2022-08-16 NextPhase Therapeutics, Inc. Pharmaceutical composition for dermatology and uses thereof
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
CN109370986A (zh) * 2018-12-11 2019-02-22 南京农业大学 一种犬脂肪干细胞的提取方法及其制剂和应用
EP3908295A2 (fr) * 2019-01-11 2021-11-17 Vetbiobank Cellules stromales neonatales felines et leurs utilisations
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CN112941021A (zh) * 2020-03-13 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) 一种骨关节炎关节液来源的间充质干细胞的培养方法
WO2021226455A1 (fr) * 2020-05-07 2021-11-11 Primegen Biotech, Llc Méthodes et compositions pour réduire l'inflammation des articulations à l'aide de cellules souches mésenchymateuses
WO2022020210A1 (fr) 2020-07-18 2022-01-27 Ossium Health, Inc. Perméation de corps vertébraux entiers avec un cryoprotecteur à l'aide d'une diffusion assistée par vide
CA3195653A1 (fr) 2020-10-14 2022-04-21 Ossium Health, Inc. Systemes et procedes d'extraction et de cryoconservation de moelle osseuse
EP4229183A4 (fr) * 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions et procédés d'extraction de cellules souches mésenchymateuses
WO2022133282A1 (fr) 2020-12-18 2022-06-23 Ossium Health, Inc. Procédés de thérapies cellulaires
CA3205553A1 (fr) * 2021-01-19 2022-07-28 Theodore T. Sand Procedes d'optimisation d'une recolte de cellules derivees de tissu reproducteur et viabilite pour des applications cliniques
US20240245641A1 (en) * 2021-05-21 2024-07-25 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
US20230022259A1 (en) * 2021-07-08 2023-01-26 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of osteoarthritis in animals
US20240041941A1 (en) * 2022-08-04 2024-02-08 University Of Louisville Research Foundation, Inc. Method of treatment for heart failure using stem cells
EP4570259A1 (fr) * 2023-12-13 2025-06-18 Gistem Research S.L. Composition pour une utilisation dans le traitement de maladies ou d'affections bucco-dentaires

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5550127A (en) * 1995-09-07 1996-08-27 Pantano; James A. Method of treatment for eiph in racing stock
EP1062321B1 (fr) * 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Utilisations de cellules souches humaines mesenchymateuses non autologues
ES2353061T5 (es) * 2000-04-25 2014-04-07 Osiris Therapeutics, Inc. Reparación de articulaciones utilizando células madre mesenquimatosas
ATE482725T1 (de) * 2003-04-01 2010-10-15 Us Dept Of Veteran S Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
JP4948166B2 (ja) * 2003-06-27 2012-06-06 エチコン、インコーポレイテッド 分娩後由来細胞を用いた軟骨と骨の修復と再生
KR20050044849A (ko) * 2003-11-07 2005-05-13 학교법인 인하학원 중간엽 줄기세포로부터 연골세포를 분화시키는 방법
EP2298863B1 (fr) * 2004-03-22 2015-07-22 Mesoblast International Sàrl Cellules souches mésenchymateuses et utilisations associées
CN1676603A (zh) * 2004-03-30 2005-10-05 中国人民解放军军事医学科学院基础医学研究所 一种人骨髓间充质干细胞体外扩增的新方法
JP2006078034A (ja) * 2004-09-08 2006-03-23 Ntt Power & Building Facilities Inc 室外機及び室外機の設置方法
JP2006123699A (ja) * 2004-10-28 2006-05-18 Miyata Ind Co Ltd 樹脂製自転車フレーム又はその部品、及びそれらの製造方法
WO2006088867A2 (fr) * 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Procede pour l'expansion de cellules souches
CA2608048A1 (fr) * 2005-05-10 2006-11-16 United States Of America Department Of Veteran's Affairs Traitement de nephropathies et de defaillance polyviscerale a l'aide de cellules souches mesenchymateuses et de milieux conditionnes par des cellules souches mesenchymateuses
WO2008020815A1 (fr) * 2006-08-15 2008-02-21 Agency For Science, Technology And Research Milieu conditionné de cellules souches mésenchymateuses
CN100344757C (zh) * 2005-10-18 2007-10-24 天津昂赛细胞基因工程有限公司 人胎盘、脐带间充质干细胞库及其构建方法
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
EP2010647A4 (fr) * 2006-03-23 2010-05-19 Pluristem Ltd Procédés de développement cellulaire et utilisations thérapeutiques des cellules et des milieux conditionnés produits de cette maniere
US7724211B2 (en) * 2006-03-29 2010-05-25 Nvidia Corporation System, method, and computer program product for controlling stereo glasses shutters
US7947435B2 (en) * 2007-01-19 2011-05-24 Seoul National University Industry Foundation Neuronal regeneration material screening method by ex vivo model
JP4926872B2 (ja) * 2007-07-27 2012-05-09 シャープ株式会社 イオン発生素子の製造方法、イオン発生素子、帯電装置および画像形成装置
US20110262402A1 (en) * 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders
US8318485B2 (en) * 2008-02-25 2012-11-27 Natalie Gavrilova Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
US20130164267A1 (en) * 2008-06-11 2013-06-27 Cell4Vet Corporation Adipose tissue-derived stem cells for veterinary use
EP2186883A1 (fr) * 2008-11-04 2010-05-19 Fresenius Medical Care Cellule souche de type stromale multipotente isolée de glomérules humains adultes (hGL-MSC), son procédé de préparation et ses utilisations en médecine régénérative du rein
US20110305673A1 (en) * 2008-11-12 2011-12-15 The University Of Vermont And State Agriculture College Compositions and methods for tissue repair
WO2010057965A1 (fr) * 2008-11-20 2010-05-27 Projech Science To Technology, S.L. Cellules souches mésenchymateuses d’origine myométriale
US20100297094A1 (en) * 2009-01-30 2010-11-25 Harlan John M Therapy or prevention of diseases with cells or cell supernatant
EP2446024A1 (fr) * 2009-06-26 2012-05-02 Life&Light Limited Cellules souches mésenchymateuses cultivées dans des conditions hypoxiques : compositions, procédés et utilisations de celles-ci
WO2011047345A2 (fr) * 2009-10-15 2011-04-21 Tai June Yoo Méthodes de traitement de maladies ou d'affections faisant appel à des cellules souches mésenchymateuses

Also Published As

Publication number Publication date
PT2611906T (pt) 2024-04-16
US20120269785A1 (en) 2012-10-25
EP2611906A4 (fr) 2014-03-19
US20120269787A1 (en) 2012-10-25
EP2611906B1 (fr) 2024-01-03
EP2611906A1 (fr) 2013-07-10
ES2974955T3 (es) 2024-07-02
AU2011295954A1 (en) 2013-04-11
WO2012030968A1 (fr) 2012-03-08
PL2611906T3 (pl) 2024-05-27
JP2013536860A (ja) 2013-09-26
CA2809272A1 (fr) 2012-03-08
BR112013004917A2 (pt) 2016-09-20
US20120052049A1 (en) 2012-03-01
US20220096558A1 (en) 2022-03-31
CN103180435A (zh) 2013-06-26
JP2016185972A (ja) 2016-10-27
DK2611906T3 (da) 2024-04-08
US20120269786A1 (en) 2012-10-25
US20170014454A1 (en) 2017-01-19
AU2011295954B2 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
HUE066003T2 (hu) Szisztémás, allogén eredetû õssejtterápiák kutyákban és macskákban betegségek kezelésére
IL258129A (en) Compositions and methods for enhancing bioenergetic status in female germ cells
IL254144A0 (en) Methods for reprogramming cells and uses thereof
EP2723263A4 (fr) Systèmes, dispositifs, et procédés d'induction d'une mort cellulaire programmée de tissus adipeux
EP2908864A4 (fr) Système d'administration d'agents thérapeutiques dans des cellules vivantes et des noyaux cellulaires
IL220040A0 (en) Methods and low dose regimens for treating red blood cell disorders
IL226127A0 (en) A compound containing hydrolyzed proteins and an oligosaccharide for the treatment of skin diseases
ZA201408262B (en) Formulations and methods for vaginal delivery antiprogestins
AP2013007178A0 (en) BCMA-based stratification and therapy for multiplemyeloma patients
PL2793929T3 (pl) Podłoże kondycjonowane uzyskane z łożyskowych mezenchymalnych komórek macierzystych w terapii stanu przedrzucawkowego
ZA201304147B (en) Multipurpose gel for vaginal dryness with direct and delayed effect
GB201100180D0 (en) Tumour cell and tissue culture
EP2640407A4 (fr) Procédé d'augmentation de l'expression et de l'activité de la néprilysine
IL232642A0 (en) A method for characterizing circulating cells and its use in diagnosis
SG11201501394SA (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
IL229462B (en) Formulation and method for transferring and harvesting human stem cells that can develop in different directions
EP2648513A4 (fr) Méthodes et compositions utiles pour favoriser le sommeil chez l'animal
PT2735235T (pt) Utilização de um complexo enzimático na alimentação de animais de criação
AP2012006557A0 (en) Antigenic structure and uses thereof for screeningtrypanosomiasis in humans and animals
EP2836068A4 (fr) Cage de contention pour parage du pied et son utilisation
GB0913102D0 (en) Animal models and therapeutic molesules
GB2480696B (en) Improvements in and relating to animal control gate assemblies
IL238389A0 (en) Phosphate-based oligomers and conjugates for introducing drugs into living cells and cell nuclei
AU2010900863A0 (en) Combination meloxicam and xylazine therapy in animals
AU2012901666A0 (en) Combination of meloxicam and xylazine therapy in animals